Skip to content

Advertisement

World Journal of Surgical Oncology

What do you think about BMC? Take part in

Open Access

Mixed adeno(neuro)endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus

  • Toshihiro Kitajima1Email author,
  • Sachiko Kaida1,
  • Seigi Lee1,
  • Shusuke Haruta1,
  • Hisashi Shinohara1,
  • Masaki Ueno1,
  • Koichi Suyama2,
  • Yasunori Oota3,
  • Takeshi Fujii3 and
  • Harushi Udagawa1
World Journal of Surgical Oncology201311:218

https://doi.org/10.1186/1477-7819-11-218

Received: 26 July 2013

Accepted: 25 August 2013

Published: 4 September 2013

Abstract

We report a case of mixed adenoendocrine carcinoma of the upper thoracic esophagus arising from ectopic gastric mucosa. A 64-year-old man who had been diagnosed with an esophageal tumor on the basis of esophagoscopy was referred to our hospital. Upper gastrointestinal endoscopy revealed the presence of ectopic gastric mucosa and an adjacent pedunculated lesion located on the posterior wall of the upper thoracic esophagus. Subtotal esophagectomy with three-field lymph node dissection was performed. A microscopic examination revealed that there was a partially intermingling component of neuroendocrine carcinoma adjacent to a tubular adenocarcinoma which was conterminous with the area of the ectopic gastric mucosa. Although the tubular adenocarcinoma was confined to the mucosa and submucosa, the neuroendocrine carcinoma had invaded the submucosaand there was vascular permeation. Each component accounted for 30% or more of the tumor, so the final histopathological diagnosis was mixed adenoendocrine carcinoma of the upper thoracic esophagus arising from ectopic gastric mucosa. Adjuvant chemotherapy was not performed, because the postoperative tumor stage was IA. The patient was well and had no evidence of recurrence 16 months after surgery.

Keywords

AdenocarcinomaEctopic gastric mucosaEsophagusMixed adenoendocrine carcinoma

Background

Most esophageal carcinomas are squamous cell carcinomas or adenocarcinomas arising from Barrett’s epithelium, whereas adenocarcinomas derived from the esophageal glands or ectopic gastric mucosa (EGM)are rare. These cases arise mostly in the cervical or upper thoracic esophagus[1]. Moreover, gastrointestinal tumors displaying both exocrine and neuroendocrine differentiation are uncommon. To the best of our knowledge, esophageal mixed adenoneuroendocrine carcinoma (MANEC)[2] arising from EGM is extremely rare. We report a case of MANEC in the upper thoracic esophagus arising from EGM and also provide a review of the pertinent literature.

Case presentation

A 64-year-old Japanese man who had been diagnosed with an esophageal tumor during a screening esophagoscopy was referred to our hospital. He had a history of Miles operation for rectal cancer 11 years earlier and partial hepatectomy and right lateral lymph node dissection for metastasis from rectal cancer 6 years prior to his presentation at our hospital. He had been smoking 20 cigarettes per day since his 20s, consumed alcohol only on social occasions and was not a regular habitual drinker. A laboratory analysis showed no abnormalities in any parameters, including the levels of tumor markers such as squamous cell carcinoma antigen, carcinoembryonic antigen and carbohydrate antigen 19–9 (CA 19–9). An upper gastrointestinal endoscopy demonstrated EGM 19 to 21 cm distal from the incisors (Figure 1a) and a pedunculated lesion located on the posterior wall of the upper thoracic esophagus 21 to 23 cm distal from the incisors (Figure 1b), which was adjacent to the area of the EGM. A biopsy taken from the pedunculated lesion revealed well-differentiated tubular adenocarcinoma. Endoscopic ultrasound revealed that the tumor had invaded the submucosa. Computed tomography detected abnormal thickening at the posterior wall of the upper thoracic esophagus without any metastases to the lymph nodes or other organs.
Figure 1

Upper gastrointestinal endoscopic findings regarding the pedunculated tumor. (a) Endoscopy revealed ectopic gastric mucosa 19 to 21 cm distal from the incisors on the oral side of the pedunculated tumor (arrowheads). (b) A pedunculated lesion was located on the posterior wall of the upper thoracic esophagus 21 to 23 cm distal from the incisors, adjacent to the area of ectopic gastric mucosa (arrowheads).

The patient was diagnosed with primary adenocarcinoma arising from EGM in the upper thoracic esophagus. He underwent radical esophagectomy with three-field lymphadenectomy. Surgical reconstruction was performed through the posterior mediastinal route using a gastric conduit, followed by esophagogastrostomy through a cervical incision. Grossly, the pedunculated tumor, which measured 17 × 15 mm (area within the red outline in Figure 2) was seen adjacent to a rough area 36 × 30 mm in size (areas within white outlines in Figure 2). Histopathologically, the pedunculated tumor consisted of well-differentiated tubular adenocarcinomaconfined within the submucosa (Figure 3a and e). The adjacent solid and trabecular component (corresponding to the area within the yellow outline in Figure 2) was composed of tumor cells showing elongated hyperchromatic nuclei and scant cytoplasm (Figure 3a and c), which were immunoreactive for CD56 (Figure 3b) and synaptophysin, confirming the diagnosis of neuroendocrine carcinoma (NEC). Additionally, vascular permeation of NEC was seen in the submucosal vein (Figure 3a, arrow). There was a histological transition between the NEC and tubular adenocarcinoma (Figure 3d), and the area of adenocarcinoma was conterminous with the EGM (corresponding to the area within the white outlines in Figure 2). The NEC and adenocarcinoma components accounted for at least 30% of the tumor lesion, respectively, confirming the diagnosis of MANEC. None of the 79 lymph nodes widely dissected, as was defined in our previous report[3], had metastases, and no lymphatic invasion was noted. The patient was diagnosed with stage IA (pT1bN0M0) disease according to the edition of the American Joint Committee on Cancer and the International Union Against Cancer TNM classification system[4]. Postoperatively, bilateral recurrent laryngeal nerve injury was noted, and a tracheostomy was placed. Six months after the surgery, resection of the pyloric ring and diversion of the gastric conduit was performed in a Roux-en-Y fashion to prevent repetitive aspiration of regurgitant. For these reasons, it took approximately 8 months for the patient to safely resume oral intake. At the time of this writing, the patient has been doing well for 16 months, with no evidence of recurrence.
Figure 2

Gross findings of the resected specimen. The pedunculated tumor, which measured 17 × 15 mm, is indicated within the red outline adjacent to a rough area 36 × 30 mm in size, which is indicated within the white outlines. The area within the yellow outline was composed of neuroendocrine carcinoma. The relationship between the NEC and adenocarcinoma components was confirmed on the green line in Figure 3.

Figure 3

Histopathologic findings. (a) A low-power view of the line (from A to B) shown in Figure 2. The neuroendocrine carcinoma (NEC) and adenocarcinoma components of the tumor were adjacent and partially intermingled. The NEC component had invaded the submucosa with vascular permeation (arrow). (b) The NEC component showed a positive response for CD56 staining (immunohistochemical stain). (c) A magnified view of the squared area at the left in (a). The NEC component showed a solid and trabecular pattern, and the tumor cells had elongated hyperchromatic nuclei and scant cytoplasm (hematoxylin and eosin stain (H&E); original magnification, ×117). (d) A magnified view of the squared area in the middle in (a). A borderline area of NEC and well-differentiated adenocarcinoma showed a histological transition (H&E; original magnification, ×117). (e) A magnified view of the squared area at the right in (a) showing well-differentiated tubular adenocarcinoma confined to the mucosa and submucosa (H&E; original magnification, ×117).

Discussion

Adenocarcinoma of the esophagus originates mostly from Barrett’s epithelium in the lower esophagus. Primary adenocarcinoma of the cervical and upper thoracic esophagus is rare and is considered to be derived from the esophageal glands (mucosal or submucosal) or from EGM[1]. The reported incidence of adenocarcinoma in the upper esophagus has been found to account for only 1% to 2% of all malignant esophageal tumors[5], and 33 cases of adenocarcinoma derived from EGM have been described worldwide in the published literature to date (Table 1). Among the 2,237 surgical cases of esophageal cancer in our hospital during the past 40 years, only 2 were primary adenocarcinomas arising from EGM. EGM often occurs in the upper esophagus. Its incidence has been reported to range from 2% to 14%, but these data have been increasing due to developments in endoscopic technology[6]. Although most patients with EGM are asymptomatic, some develop symptoms based on acid secretion from the EGM, such as dysphagia or a sore throat. Furthermore, EGM is sometimes accompanied by severe complications such as bleeding, perforation, stricture, tracheoesophageal fistula formation or webbing[7]. In our patient, it is noteworthy that the area of NEC existed adjacent to the area of tubular adenocarcinoma, which was conterminous with the EGM.
Table 1

Summary of esophageal adenocarcinomas arising from ectopic gastric mucosa published in the literature ( N= 34) a

Case

Reference

Year

Age

Sex

Histology

TNM

Treatment

Postoperative course

1

Carrie[8]

1950

64

M

Adenocarcinoma

pT2NXM0

Resection of the upper esophagus

No recurrence (>1 yr)

2

Morson and Belcher[9]

1952

56

M

Adenocarcinoma

pT3N1M0

Esophagectomy

Unknown

3

Raphael et al.[10]

1966

69

M

Well- differentiated adenocarcinoma

unknown

Radiotherapy

Died (suicide) (2 mo)

4

Davis et al.[11]

1969

68

M

Mucinous adenocarcinoma

pT1(SM)NXMX

Radiotherapy + esophagectomy

No recurrence (7 mo)

5

Sakamoto et al.[12]

1970

64

M

Adenocarcinoma

pT2N0M0

Esophagectomy

Died (10 mo)

6

Jernstrom and Brewer[13]

1970

73

M

Poorly differentiated adenocarcinoma

pT3N0M0

Radiotherapy + esophagectomy

Died (4 mo)

7

Clemente[14]

1974

53

M

Adenocarcinoma

pT3

Esophagectomy

Recurrence (10 mo)

8

Danoff et al.[15]

1978

43

M

Poorly differentiated adenocarcinoma

cT4NXMX

Radiotherapy

Died (9 mo)

9

Goëau-Brissonnière et al.[16]

1985

38

M

Adenocarcinoma

pT3

Esophagectomy

No recurrence (31 mo)

10

Schmidt et al.[17]

1985

37

M

Adenocarcinoma

pT3

Esophagectomy

Died (4 mo)

11

Christensen and Sternberg[18]

1987

52

M

Poorly differentiated adenocarcinoma

pT2N1M0

Esophagectomy

Recurrence (25 mo)

12

Christensen and Sternberg[18]

1987

50

M

Moderately differentiated adenocarcinoma

pT3N1M0

Esophagectomy

Unknown

13

Ishii et al.[19]

1991

66

M

Moderately differentiated adenocarcinoma

pT3N1M0

Esophagectomy

No recurrence (20 mo)

14

Takagi et al.[20]

1995

70

M

Well- differentiated adenocarcinoma

pT1(SM)N0M0

Esophagectomy

Unknown

15

Sperling and Grendell[21]

1995

79

M

Poorlydifferentiated adenocarcinoma

cT4N0M0

Radiotherapy

Unknown

16

Pai et al.[22]

1997

60

M

Poorly differentiated adenocarcinoma

pT2N0M0

Surgery/radiochemotherapy

Recurrence (24 mo)

17

Berkelhammer et al.[23]

1997

71

M

Moderately differentiated adenocarcinoma

pT1(SM)N1M0

Esophagectomy

No recurrence (2 yr)

18

Lauwers et al.[24]

1998

57

F

Moderately differentiated adenocarcinoma

pT3N0M0

Esophagectomy + adjuvant radiotherapy

No recurrence (8 mo)

19

Klaase et al.[25]

2001

43

M

Poorly differentiated adenocarcinoma

pT4N1M0

Esophagectomy + adjuvant radiotherapy

Died (4 mo)

20

Pech et al.[26]

2001

77

M

Well-differentiated adenocarcinoma

cT1(SM)N0M0

Endoscopic mucosal resection

No recurrence (1 yr)

21

Noguchi et al.[27]

2001

73

M

Well-differentiated adenocarcinoma

cT1(SM)N0M0

Resection of the cervical esophagus

No recurrence (5 yr)

22

Chatelain et al.[28]

2002

61

M

Poorly differentiated adenocarcinoma

pT3NXM0

Esophagectomy

Died (15 mo)

23

Hirayama et al.[29]

2003

77

F

Well-differentiated adenocarcinoma

cT1(M)N0M0

Endoscopic mucosal resection

No recurrence (31 mo)

24

Balon et al.[30]

2003

61

M

Adenocarcinoma

pT3N0M0

Esophagectomy

Died (21 mo)

25

Abe et al.[31]

2004

50

M

Well-differentiated adenocarcinoma

pT1(SM)N0M0

Esophagectomy

No recurrence (18 mo)

26

von Rahden et al.[1]

2005

52

M

Moderately differentiated adenocarcinoma

cT3N1M0

Neoadjuvant chemoradiotherapy + surgery

No recurrence (36 mo)

27

Alrawi et al.[32]

2005

60

M

Moderately differentiated adenocarcinoma

pT1(SM)N0M0

Esophagectomy + adjuvant Chemoradiotherapy

No recurrence (6 yr)

28

Hoshino et al.[33]

2007

74

M

Papillary adenocarcinoma

pT3N0M0

Esophagectomy

No recurrence (5 mo)

29

Alagozlu et al.[34]

2007

57

M

Poorly differentiated adenocarcinoma

cT4N1M0

None

Died before treatment

30

Komori et al.[35]

2010

75

M

Moderately differentiated adenocarcinoma

cT2N1M0

Esophagectomy

No recurrence (42 mo)

31

Iitaka et al.[36]

2011

64

M

Poorly differentiated adenocarcinoma

pT1(M)N0M0

Esophagectomy

No recurrence (36 mo)

32

Akanuma et al.[37]

2013

57

M

Well-differentiated adenocarcinoma

pT2N0M0

Esophagectomy + chemoradiotherapy

No recurrence (4 yr)

33

Nonaka et al.[38]

2013

74

M

adenocarcinoma

unknown

Endoscopic submucosal dissection

Unknown

34

Present case

2013

64

M

Well-differentiated adenocarcinoma

pT1bN0M0

Esophagectomy

No recurrence (16 mo)

aThe cases included in this table are those available in PubMed as of 5 August 2013. TNM tumor, node, metastasis.

The term mixed exocrine-endocrine carcinoma (MEEC), which was proposed by the World Health Organization (WHO) in its classification system of endocrine tumors, refers to a neoplasm with divergent exocrine and neuroendocrine differentiation[39]. In the latest WHO classification system published in 2010[2], neuroendocrine neoplasms in the digestive system were reclassified as NET G1, NET G2, NEC and MANEC according to the degree of cellular differentiation and proliferative activity[40]. MEEC/MANEC is distinguished from carcinomas with focal neuroendocrine differentiation by at least two major diagnostic criteria: (1) extension of each component (at least 30%) and (2) structural features of neuroendocrine components as well-differentiated organoid or solid or diffuse growth patterns[41]. Several cases of MANECs of digestive organs have been reported to be detected in the colon, pancreas, gallbladder, biliary tract, stomach, ampulla, cecum and esophagogastric junction[4264] (Table 2). Lewin proposed a classification of morphological patterns of the two components in MEEC/MANEC distinguishing (1) truly composite (or mixed) exocrine-endocrine tumors with both elements in more or less equal proportions, (2) amphicrine tumors with dual differentiation within the same cell and (3) collision tumors, in which two components are closely juxtaposed but not admixed[65]. According to this classification scheme, our present case was considered to be a composite (mixed) adenoendocrine carcinoma.
Table 2

Summary of the cases of mixed adeno(neuro)endocrine carcinoma published in the English-language literature after 2010 ( N= 47) a

Affected organ

Cases

Mean age (yr)

Sex (M/F)

SYN (+/−/unknown)

CGA (+/−/unknown)

CD56 (+/−/unknown)

Colon[6, 7]

13

71

9/4

13/0/0

13/0/0

0/0/13

Pancreas[3946]

13

69

11/2

11/0/2

12/0/1

0/0/13

Gallbladder[4750]

8

63

1/7

8/0/0

7/0/1

2/0/6

Biliary tract[46, 51, 52]

6

71

3/3

6/0/0

5/1/0

1/0/3

Stomach[5356]

4

71

1/3

4/0/0

3/1/0

2/1/1

Ampulla[57]

1

81

1/0

1/0/0

1/0/0

0/0/1

Cecum[58]

1

68

0/1

1/0/0

1/0/0

0/0/1

Esophagogastric junction[59]

1

68

1/0

1/0/0

0/0/1

0/0/1

aThe cases included in this table are those available in PubMed as of 5 August 2013. We grouped the cases that are expressed as mixed exocrine-endocrine carcinoma, mixed ductal-endocrine carcinoma and mixed acinar-endocrine carcinoma into a single mixed adenoneuroendocrine carcinoma (MANEC) category if they met the World Health Organization classification of endocrine tumors and the paper was published after 2010. We excluded the collision type of MANEC. CGA chromogranin A, SYN synaptophysin.

The clinical behavior of MANECs is still unclear due to the rarity of these tumors. In 2006, Volante et al. reported that the clinical behavior of MEECs follows that of most aggressive cell types[41]. In the present case, although the well-differentiated tubular adenocarcinoma was confined to the mucosa and submucosa, the NEC components had invaded the submucosa with vascular permeation. Therefore, we think that the pathological features of the NEC component will have a greater influence than those of the tubular adenocarcinoma on the prognosis of this patient.

The optimal treatment for esophageal MANEC has not yet been established. Basically, the standard treatment of patients with esophageal MANEC should be determined in accordance with the treatment recommended for esophageal squamous cell carcinoma. The resectability should be judged on the basis of the preoperative diagnosis, and the decision whether to provide adjuvant therapy should be made on the basis of the postoperative diagnosis. Preoperative chemotherapy is regarded as the standard treatment for patients with stage II/III esophageal squamous cell carcinoma in Japan[66]. In our patient, however, preoperative chemotherapy was not performed, because the preoperative diagnosis was stage IA and the histological diagnosis was not squamous cell carcinoma. Although surgery is the treatment of choice for limited disease of esophageal small cell carcinoma, defined as a tumor confined to a localized region, surgery alone has been found to lead to worse outcomes than adjuvant chemotherapy[67, 68]. Investigators in several studies have reported that surgery could extend the survival time of patients with limited disease if it was performed as part of multimodal treatment[69, 70]. Chemotherapy for esophageal NEC is usually administered according to the recommendations for chemotherapy for small cell lung cancer (SCLC) and usually consists of cisplatin and etoposide[68, 69]. In our case, there was a choice regarding which adjuvant chemotherapy should be administered because of the pathological features of the NEC components representing vascular permeation. We did not administer adjuvant chemotherapy, however, because of the complicated postoperative course resulting from the bilateral recurrent laryngeal nerve injury, the fact that the stage of the disease was IA (pT1bN0M0) and the operation performed had sufficiently high curative potential. However, we think that close follow-up of the patient is mandatory. In addition, Noda et al. suggested the superiority of cisplatin and irinotecan over cisplatin and etoposide for metastatic SCLC[71], and cisplatin and irinotecan is another option for esophageal NEC in Japan.

Conclusion

Our patient had a rare case of MANEC arising from EGM of the upper thoracic esophagus. To the best of our knowledge, this case report is the first of its kind published in the literature. Because the clinical behavior of esophageal MANEC is poorly understood, further accumulation of similar cases is necessary to clarify the optimal treatment for this disease.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

EGM: 

Ectopic gastric mucosa

MANEC: 

Mixed adenoendocrine carcinoma

NEC: 

Neuroendocrine carcinoma

SCLC: 

Small cell lung cancer

WHO: 

World Health Organization.

Declarations

Authors’ Affiliations

(1)
Department of Digestive Surgery, Toranomon Hospital
(2)
Department of Medical Oncology, Toranomon Hospital
(3)
Department of Pathology, Toranomon Hospital

References

  1. von Rahden BH, Stein HJ, Becker K, Siewert RJ: Esophageal adenocarcinomas in heterotopic gastric mucosa: review and report of a case with complete response to neoadjuvant radiochemotherapy. Dig Surg. 2005, 22: 107-112. 10.1159/000085448.View ArticlePubMedGoogle Scholar
  2. WHO Classification of Tumors of the Digestive System. Edited by: Bosman FT, Carneiro F, Hruban RH, Theise ND. 2010, Lyon, France: World Health Organization, International Agency for Research on CancerGoogle Scholar
  3. Udagawa H, Akiyama H: Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus. 2001, 14: 110-114. 10.1046/j.1442-2050.2001.00166.x.View ArticlePubMedGoogle Scholar
  4. AJCC Cancer Staging Manual. Edited by: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. 2010, New York: Springer, 7Google Scholar
  5. Faintuch J, Shepard KV, Levin B: Adenocarcinoma and other unusual variants of esophageal cancer. Semin Oncol. 1984, 11: 196-202.PubMedGoogle Scholar
  6. Jabbari M, Goresky CA, Lough J, Yaffe C, Daly D, Côté C: The inlet patch: heterotopic gastric mucosa in the upper esophagus. Gastroenterol. 1985, 89: 352-356.Google Scholar
  7. Waring JP, Wo JM: Cervical esophageal web caused by an inlet patch of gastric mucosa. South Med J. 1997, 90: 554-555. 10.1097/00007611-199705000-00021.View ArticlePubMedGoogle Scholar
  8. Carrie A: Adenocarcinoma of the upper end of the oesophagus arising from ectopic gastric epithelium. Br J Surg. 1950, 37: 474-10.1002/bjs.18003714810.View ArticlePubMedGoogle Scholar
  9. Morson BC, Belcher JR: Adenocarcinoma of the oesophagus and ectopic gastric mucosa. Br J Cancer. 1952, 6: 127-130. 10.1038/bjc.1952.14.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Raphael HA, Ellis FH, Dockerty MB: Primary adenocarcinoma of the esophagus: 18-year review and review of literature. Ann Surg. 1966, 164: 785-796. 10.1097/00000658-196611000-00002.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Davis WM, Goodwin MN, Black HC, Hawk JC: Polypoid adenocarcinoma of the cervical esophagus. Arch Pathol. 1969, 88: 367-370.PubMedGoogle Scholar
  12. Sakamoto G, Nakamura K, Saito K, Sato M, Sugahara T: [Primary adenocarcinoma of the esophagus arising from heterotopic gastric glands] [in Japanese]. Gan No Rinsho. 1970, 16: 1105-1110.PubMedGoogle Scholar
  13. Jernstrom P, Brewer LA: Primary adenocarcinoma of the mid-esophagus arising in ectopic gastric mucosa with associated hiatal hernia and reflux esophagitis (Dawson's syndrome). Cancer. 1970, 26: 1343-1348. 10.1002/1097-0142(197012)26:6<1343::AID-CNCR2820260622>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
  14. Clemente C: [A case of adenocarcinoma of the upper third of the esophagus arising on ectopic gastric tissue (author’s translation)] [in Italian]. Tumori. 1974, 60: 17-24.PubMedGoogle Scholar
  15. Danoff B, Cooper J, Klein M: Primary adenocarcinoma of the upper oesophagus. Clin Radiol. 1978, 29: 519-522. 10.1016/S0009-9260(78)80042-7.View ArticlePubMedGoogle Scholar
  16. Goëau-Brissonnière O, Hannoun L, Huguet C: [Adenocarcinoma of the cervical esophagus. Association with a gastric heterotopia] [in French]. J Chir (Paris). 1985, 122: 101-103.Google Scholar
  17. Schmidt H, Riddell RH, Walther B, Skinner DB, Riemann JF, Groitl H: [Adenocarcinoma of heterotopic gastric mucosa in the proximal esophagus] [in German]. Leber Magen Darm. 1985, 15: 144-147.PubMedGoogle Scholar
  18. Christensen WN, Sternberg SS: Adenocarcinoma of the upper esophagus arising in ectopic gastric mucosa: two case reports and review of the literature. Am J Surg Pathol. 1987, 11: 397-402. 10.1097/00000478-198705000-00009.View ArticlePubMedGoogle Scholar
  19. Ishii K, Ota H, Nakayama J, Katsuyama T, Matsuzawa K, Honda T, Akamatsu T: Adenocarcinoma of the cervical oesophagus arising from ectopic gastric mucosa. The histochemical determination of its origin. Virchows Arch A Pathol Anat Histopathol. 1991, 419: 159-164. 10.1007/BF01600231.View ArticlePubMedGoogle Scholar
  20. Takagi A, Ema Y, Horii S, Morishita M, Miyaishi O, Kino I: Early adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagus. Gastrointest Endosc. 1995, 41: 167-170. 10.1016/S0016-5107(05)80605-4.View ArticlePubMedGoogle Scholar
  21. Sperling RM, Grendell JH: Adenocarcinoma arising in an inlet patch of the esophagus. Am J Gastroenterol. 1995, 90: 150-152.PubMedGoogle Scholar
  22. Pai S, Deshpande R, Naresh KN: Adenocarcinoma of cervical esophagus arising in aberrant gastric mucosa. Indian J Gastroenterol. 1997, 16: 157-158.PubMedGoogle Scholar
  23. Berkelhammer C, Bhagavan M, Templeton A, Raines R, Walloch J: Gastric inlet patch containing submucosally infiltrating adenocarcinoma. J Clin Gastroenterol. 1997, 25: 678-681. 10.1097/00004836-199712000-00025.View ArticlePubMedGoogle Scholar
  24. Lauwers GY, Scott GV, Vauthey JN: Adenocarcinoma of the upper esophagus arising in cervical ectopic gastric mucosa: rare evidence of malignant potential of so-called “inlet patch. Dig Dis Sci. 1998, 43: 901-907. 10.1023/A:1018855223225.View ArticlePubMedGoogle Scholar
  25. Klaase JM, Lemaire LC, Rauws EA, Offerhaus GJ, van Lanschot JJ: Heterotopic gastric mucosa of the cervical esophagus: a case of high-grade dysplasia treated with argon plasma coagulation and a case of adenocarcinoma. Gastrointest Endosc. 2001, 53: 101-104. 10.1067/mge.2001.111394.View ArticlePubMedGoogle Scholar
  26. Pech O, May A, Gossner L, Vieth M, Trump F, Stolte M, Ell C: Early stage adenocarcinoma of the esophagus arising in circular heterotopic gastric mucosa treated by endoscopic mucosal resection. Gastrointest Endosc. 2001, 54: 656-658. 10.1067/mge.2001.118717.View ArticlePubMedGoogle Scholar
  27. Noguchi T, Takeno S, Takahashi Y, Sato T, Uchida Y, Yokoyama S: Primary adenocarcinoma of the cervical esophagus arising from heterotopic gastric mucosa. J Gastroenterol. 2001, 36: 704-709. 10.1007/s005350170035.View ArticlePubMedGoogle Scholar
  28. Chatelain D, de Lajarte-Thirouard AS, Tiret E, Flejou JF: Adenocarcinoma of the upper esophagus arising in heterotopic gastric mucosa: common pathogenesis with Barrett’s adenocarcinoma?. Virchows Arch. 2002, 441: 406-411. 10.1007/s00428-002-0697-7.View ArticlePubMedGoogle Scholar
  29. Hirayama N, Arima M, Miyazaki S, Shimada H, Okazumi S, Matsubara H, Suzuki T, Ochiai T, Kouzu T: Endoscopic mucosal resection of adenocarcinoma arising in ectopic gastric mucosa in the cervical esophagus: case report. Gastrointest Endosc. 2003, 57: 263-266. 10.1067/mge.2003.84.View ArticlePubMedGoogle Scholar
  30. Balon JM, Mariette C, Fabre S, Tiret E, Triboulet JP: [Primary adenocarcinoma of the cervical esophagus arising from heterotopic gastric mucosa] [in French]. Gastroenterol Clin Biol. 2003, 27: 836-838.PubMedGoogle Scholar
  31. Abe T, Hosokawa M, Kusumi T, Kusano M, Hokari K, Kagaya H, Watanabe A, Fujita M, Sasaki S: Adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagus. Am J Clin Oncol. 2004, 27: 644-645. 10.1097/01.coc.0000147808.63442.b5.View ArticlePubMedGoogle Scholar
  32. Alrawi SJ, Winston J, Tan D, Gibbs J, Loree TR, Hicks W, Rigual N, Lorè JM: Primary adenocarcinoma of cervical esophagus. J Exp Clin Cancer Res. 2005, 24: 325-330.PubMedGoogle Scholar
  33. Hoshino A, Otuka Y, Nara S, Harihara Y, Konishi T: A case of primary adenocarcinoma of the cervical esophagus arising from the ectopic gastric mucosa. Esophagus. 2007, 4: 83-86. 10.1007/s10388-007-0111-2.View ArticleGoogle Scholar
  34. Alagozlu H, Ergun M, Cindoruk M, Unal S, Dumlu S, Poyraz A, Dursun A: The rare presentations of a large polyp and an esophageal carcinoma in heterotropic gastric mucosa: a case series. J Med Case Rep. 2007, 1: 127-10.1186/1752-1947-1-127.PubMed CentralView ArticlePubMedGoogle Scholar
  35. Komori S, Osada S, Tanaka Y, Takahashi T, Nagao N, Yamaguchi K, Asano N, Yoshida K: A case of esophageal adenocarcinoma arising from the ectopic gastric mucosa in the thoracic esophagus. Rare Tumors. 2010, 2: e5-PubMed CentralPubMedGoogle Scholar
  36. Iitaka D, Fujiwara H, Shiozaki A, Kubota T, Ando T, Murayama Y, Komatsu S, Kuriu Y, Ikoma H, Nakanishi M, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Otsuji E: Double primary cancer of the esophagus consisting of ectopic gastric mucosa-derived adenocarcinoma and squamous cell carcinoma: a first case report. Esophagus. 2011, 8: 303-309. 10.1007/s10388-011-0296-2.View ArticleGoogle Scholar
  37. Akanuma N, Hoshino I, Akutsu Y, Shuto K, Shiratori T, Kono T, Uesato M, Sato A, Isozaki Y, Maruyama T, Takeshita N, Matsubara H: Primary esophageal adenocarcinoma arising from heterotopic gastric mucosa: report of a case. Surg Today. 2013, 43: 446-451. 10.1007/s00595-012-0206-9.View ArticlePubMedGoogle Scholar
  38. Nonaka K, Watanabe M, Yuruki H, Okuda A, Sakurai K, Iyama K, Sasaki Y: Narrow band imaging of adenocarcinoma arising from ectopic gastric mucosa in the upper esophagus. Endoscopy. 2013, 45 (Suppl 2 UCTN): E112-E113.PubMedGoogle Scholar
  39. Solcia E, Klöppel G, Sobin LH, Capella C, DeLellis RA, Heitz PU, Horvath E, Kovacs K, Lack E, Lloyd RV, Rosai J, Scheithauer BW: Histological Typing of Endocrine Tumours (WHO International Histological Classification of Tumours series). 2000, New York: Springer Verlag, 56-70. 2View ArticleGoogle Scholar
  40. Rindi G, Arnold R, Bosman FT: Nomenclature and classification of neuroendocrine neoplasms of the digestive system. WHO Classification of Tumors of the Digestive System. Edited by: Bosman FT, Carneiro F, Hruban RH, Theise ND. 2010, Lyon, France: World Health Organization, International Agency for Research on Cancer, 13-14.Google Scholar
  41. Volante M, Rindi G, Papotti M: The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch. 2006, 449: 499-506. 10.1007/s00428-006-0306-2.View ArticlePubMedGoogle Scholar
  42. Marando A, Dainese E, La Rosa S, Capella C: Images in endocrine pathology: oncocytic differentiation in a mixed adenoneuroendocrine carcinoma of the colon. Endocr Pathol. 2013, 24: 54-56. 10.1007/s12022-012-9201-3.View ArticlePubMedGoogle Scholar
  43. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C: Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012, 36: 601-611. 10.1097/PAS.0b013e318242e21c.View ArticlePubMedGoogle Scholar
  44. Kobayashi S, Asakura T, Ohike N, Enomoto T, Sakurai J, Koizumi S, Watanabe T, Nakano H, Otsubo T: Mixed acinar-endocrine carcinoma of the pancreas with intraductal growth into the main pancreatic duct: report of a case. Surg Today. 2010, 40: 380-384. 10.1007/s00595-009-4083-9.View ArticlePubMedGoogle Scholar
  45. Chung WJ, Byun JH, Lee SS, Lee MG: Imaging findings in a case of mixed acinar-endocrine carcinoma of the pancreas. Korean J Radiol. 2010, 11: 378-381. 10.3348/kjr.2010.11.3.378.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Araki K, Shimura T, Kobayashi T, Saito K, Wada W, Sasaki S, Suzuki H, Kashiwabara K, Nakajima T, Kuwano H: Mixed ductal-endocrine carcinoma of the pancreas occurring as a double cancer: report of a case. Int Surg. 2011, 96: 153-158. 10.9738/CC8.1.View ArticlePubMedGoogle Scholar
  47. Hirano H, Terada N, Yamada N, Yamanegi Y, Oyama H, Nishigami T, Nakasho K: A case of mixed ductal-endocrine carcinoma of the pancreas. Med Mol Morphol. 2011, 44: 58-62. 10.1007/s00795-010-0533-0.View ArticlePubMedGoogle Scholar
  48. Lennerz JK, Fernandez-Del Castillo C, Pitman MB: Mixed ductal-endocrine carcinoma of the pancreas metastatic to the liver. Pancreas. 2011, 40: 319-321. 10.1097/MPA.0b013e3181f891e7.View ArticlePubMedGoogle Scholar
  49. Ahmad Z, Mumtaz S, Fatima S, Qureshi A: Mixed ductal-endocrine carcinoma of pancreas. BMJ Case Rep. 2011: bcr0220113861-10.1136/bcr.02.2011.3861.Google Scholar
  50. Sullivan PS, Clebanoff JL, Hirschowitz SL: Hints to the diagnosis of mixed acinar-endocrine carcinoma on pancreatic fine-needle aspiration: avoiding a potential diagnostic pitfall. Acta Cytol. 2013, 57: 296-302. 10.1159/000343683.View ArticlePubMedGoogle Scholar
  51. Yu R, Jih L, Zhai J, Nissen NN, Colquhoun S, Wolin E, Dhall D: Mixed acinar-endocrine carcinoma of the pancreas: new clinical and pathological features in a contemporary series. Pancreas. 2013, 42: 429-435. 10.1097/MPA.0b013e318264d073.View ArticlePubMedGoogle Scholar
  52. Harada K, Sato Y, Ikeda H, Maylee H, Igarashi S, Okamura A, Masuda S, Nakanuma Y: Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch. 2012, 460: 281-289. 10.1007/s00428-012-1212-4.View ArticlePubMedGoogle Scholar
  53. Paniz Mondolfi AE, Slova D, Fan W, Attiyeh FF, Afthinos J, Reidy J, Pang Y, Theise ND: Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: a possible stem cell tumor?. Pathol Int. 2011, 61: 608-614. 10.1111/j.1440-1827.2011.02709.x.View ArticlePubMedGoogle Scholar
  54. Song W, Chen W, Zhang S, Peng J, He Y: Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy. Diagn Pathol. 2012, 27: 7-163.Google Scholar
  55. Shintaku M, Kataoka K, Kawabata K: Mixed adenoneuroendocrine carcinoma of the gallbladder with squamous cell carcinomatous and osteosarcomatous differentiation: report of a case. Pathol Int. 2013, 63: 113-119. 10.1111/pin.12029.View ArticlePubMedGoogle Scholar
  56. Onishi I, Kitagawa H, Harada K, Maruzen S, Sakai S, Makino I, Hayashi H, Nakagawara H, Tajima H, Takamura H, Tani T, Kayahara M, Ikeda H, Ohta T, Nakanuma Y: Intraductal papillary neoplasm of the bile duct accompanying biliary mixed adenoneuroendocrine carcinoma. World J Gastroenterol. 2013, 28: 3161-3164.View ArticleGoogle Scholar
  57. Linder R, Dorfman T, Ben-Ishay O, Kakiashvili E, Velodavsky E, Kluger Y: Mixed neuroendocrine tumor of the common bile duct. JOP. 2013, 14: 71-73.PubMedGoogle Scholar
  58. Kim TY, Chae HD: Composite neuroendocrine carcinoma with adenocarcinoma of the stomach misdiagnosed as a giant submucosal tumor. J Gastric Cancer. 2011, 11: 126-130. 10.5230/jgc.2011.11.2.126.PubMed CentralView ArticlePubMedGoogle Scholar
  59. Mitsutsuji M, Okamura A: A resected case of metachronous liver metastasis from mixed adenoneuroendocrine carcinoma of the stomach. Nihon Shokakibyo Gakkai Zasshi. 2011, 108: 1910-1915.PubMedGoogle Scholar
  60. Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, Luong TV: Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol. 2012, 5: 313-319. 10.1159/000339611.PubMed CentralView ArticlePubMedGoogle Scholar
  61. Lee JH, Kim HW, Kang DH, Choi CW, Park SB, Kim SH: A gastric composite tumor with an adenocarcinoma and a neuroendocrine carcinoma: a case report. Clin Endosc. 2013, 46: 280-283. 10.5946/ce.2013.46.3.280.PubMed CentralView ArticlePubMedGoogle Scholar
  62. Vilardell F, Velasco A, Cuevas D, Olsina JJ, Matias-Guiu X: Composite papillary intestinal-type adenocarcinoma/poorly differentiated neuroendocrine carcinoma of the ampulla of Vater. J Clin Pathol. 2011, 64: 174-177.View ArticlePubMedGoogle Scholar
  63. Jain A, Singla S, Jagdeesh KS, Vishnumurthy HY: Mixed adenoneuroendocrine carcinoma of cecum: a rare entity. J Clin Imaging Sci. 2013, 28: 3-10.Google Scholar
  64. Veits L, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H: Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. Endoscopy. 2013, 45: E16-E17.View ArticlePubMedGoogle Scholar
  65. Lewin K: Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987, 11: 71-86. 10.1097/00000478-198700111-00007.View ArticlePubMedGoogle Scholar
  66. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012, 19: 68-74. 10.1245/s10434-011-2049-9.View ArticlePubMedGoogle Scholar
  67. Casas F, Ferrer F, Farrús B, Casals J, Biete A: Primary small cell carcinoma of the esophagus: a review of the literature with emphasis on therapy and prognosis. Cancer. 1997, 80: 1366-1372. 10.1002/(SICI)1097-0142(19971015)80:8<1366::AID-CNCR2>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
  68. Kubota K, Okada A, Kuroda J, Yoshida M, Origuchi N, Ohta K, Itabashi M, Osamura Y, Kitajima M: Neuroendocrine carcinoma of the esophagus: report of a case and review of the literature. Open J Gastroenterol. 2012, 2: 85-90. 10.4236/ojgas.2012.22018.View ArticleGoogle Scholar
  69. Brenner B, Tang LH, Klimstra DS, Kelsen DP: Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol. 2004, 22: 2730-2739. 10.1200/JCO.2004.09.075.View ArticlePubMedGoogle Scholar
  70. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL: Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008, 32: 1404-1411. 10.1097/PAS.0b013e31816bf41f.View ArticlePubMedGoogle Scholar
  71. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002, 346: 85-91. 10.1056/NEJMoa003034.View ArticlePubMedGoogle Scholar

Copyright

© Kitajima et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement